trending Market Intelligence /marketintelligence/en/news-insights/trending/7mrFhSMQnizmXCY1lDkbAw2 content
Log in to other products

Login to Market Intelligence Platform

 /

Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Principia Biopharma prices $210M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Principia Biopharma prices $210M common stock offering

Principia Biopharma Inc. priced its underwritten public offering of 7.5 million common shares at $28 each.

The South San Francisco, Calif.-based company also granted underwriters a 30-day option to buy up to 1,125,000 additional common shares at the same price.

Principia expects $210 million in gross proceeds from the offering.

The offer is expected to close on or about Oct. 18.

BofA Merrill Lynch, SVB Leerink, and Wells Fargo Securities are acting as joint book-running managers for the offering, while Baird is lead manager, while H.C. Wainwright & Co. is co-manager for the offer.

Principia Biopharma Inc. develops therapies for immunology and oncology.